Gerald Shulman, MD, PhD: Solving the Mystery of Insulin Resistance

Video

By addressing insulin resistance, researchers believe they can reduce the comorbidities associated with type 2 diabetes.

Insulin resistance has long been known as a critical factor in the pathogenesis of type 2 diabetes.

However, it might not entirely be known what the particular role of diacylglycerol and acetyl-CoAin play in insulin resistance.

During the 18th World Congress of Insulin Resistance Diabetes & Cardiovascular (WCIRDC) Online CME Conference presented by the Metabolic Institute of America (TMIOA), Gerald Shulman, MD, PhD, George R. Cowgill Professor of Medicine and Cellular & Molecular Physiology at Yale, explained how this can be a beneficial therapeutic target to reduce the amount of obese patients with insulin resistance.

The researchers believe these lipids explain insulin resistance concept because fat will build up where it does not belong, triggering insulin resistance.

This could also explain why certain drugs are able to reduce the fat in certain organs and reverses insulin resistance. Fat is not, however, the causal agent of insulin resistance, leading to the hypothesis that it is another lipid species that causes insulin resistance.

Recent studies show it is diacylglycerol that trigger PKC activation, leading to blocks to insulin signaling and insulin action.

Shulman also explained how fixing insulin resistance could have an impact at reducing some of the cardiovascular and kidney comorbidities commonly associated with type 2 diabetes.

Recent Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
A panel of 5 cardiovascular experts
Kaitlin Mayne, MBChB | Credit X.com
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
© 2024 MJH Life Sciences

All rights reserved.